The future of medical research and innovative therapies is on the horizon, and Calliditas Therapeutics AB is leading the charge. On May 16, 2024, the company announced that it will be hosting an in-person and virtual R&D day on Thursday, May 30, 2024, at 3:00 PM CET, with a focus on its groundbreaking programs.
The event, which will take place at the Inderes Event Studio in Stockholm, will feature renowned experts in the field, including Gareth J. Thomas, PhD, from the University Hospital Southampton, and Jonathan Barratt, PhD, FRCP, from the University of Leicester. The program will cover a range of topics, including the evaluation of setanaxib in patients with squamous cell carcinoma of the head and neck, the anti-fibrotic effects of setanaxib in solid tumors and fibrotic diseases, and upcoming clinical data from the NOX platform.
Attendees can expect a detailed discussion of recent positive clinical results, preclinical data, and biomarker information for both programs. Additionally, there will be an overview of the company’s pipeline and expected data readouts in the future. A live Q&A session will follow the presentations, providing an opportunity for further engagement and insights.
Gareth J. Thomas, a Professor of Experimental Pathology at the University of Southampton, will share his expertise on how fibroblasts impact cancer progression and the development of new therapies to target fibroblasts. Jonathan Barratt, who leads the Renal Research Group at the University of Leicester, will present his research on improving the understanding of IgA nephropathy, a common cause of kidney failure globally.
For those interested in attending, advance registration is required. Questions for the live Q&A session can be submitted in advance to questions@lifesciadvisors.com. For more information, contact Asa Hillsten, Head of IR & Sustainability at Calliditas, at asa.hillsten@calliditas.com.
Don’t miss this opportunity to learn about the latest advancements in medical research and the promising future of innovative therapies. Join Calliditas Therapeutics AB on May 30, 2024, for an insightful and informative R&D day that promises to shape the future of healthcare.